Phong Phu Pharmaceutical JSC
HHNX:PPP19,800.00
VND
+1,800.00
(+10.00%)
ISIN
VN000000PPP8
Return %
Stock
S&P 500
1Y
-0.50
14.20
3Y
36.55
81.12
5Y
40.43
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Ngon Nha Thai
- Full Time Employees
- 204
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Ho Chi Minh City Vietnam
- IPO Date
- Jul 18, 2011
- Website
- duocphongphu.vn
- Similar Companies
- Business
- Phong Phu Pharmaceutical Joint Stock Company (HNX: PPP), commercially known as PP.Pharco, is a Vietnam-based pharmaceutical company primarily engaged in the research, development, manufacture, marketing, and distribution of generic allopathic medicines, herbal therapeutics, and dietary health supplements. Founded in August 2000 as the corporate successor to the District 8 State Pharmaceutical Enterprise established in 1975, the company is headquartered in the Tan Tao Industrial Park, Binh Tan District, Ho Chi Minh City, Vietnam. Phong Phu Pharmaceutical operates through two primary business divisions: Pharmaceutical Manufacturing and Commercial Distribution. The company offers a diversified commercial portfolio comprising more than 200 registered pharmaceutical and healthcare formulations across multiple therapeutic categories. Its core product lines include gastrointestinal medications, such as Loperamid and Richcarbo; anti-inflammatory, analgesic, and antipyretic formulations, including Alphachymotrypsin and Usaresfil; antihistamine and antiallergic agents, such as Nasalis; cardiovascular and metabolic disease treatments, including Usarclopi and Digorich; respiratory remedies; psychotropic agents; herbal choleretics and tonics, including Chophytin; and a broad range of nutritional supplements, including Magnesi B6, Vitamin E 400 IU, and essential multivitamin complexes. Phong Phu Pharmaceutical manufactures its portfolio in diverse pharmaceutical forms, including soft gelatin capsules, hard capsules, film-coated tablets, sugar-coated tablets, oral powders, and granules at its USARICHPHARM manufacturing facility, which operates under World Health Organization Good Manufacturing Practice (GMP-WHO), Good Storage Practice (GSP), and Good Laboratory Practice (GLP) certifications with an annual capacity exceeding 1.2 billion units. Alongside its proprietary branded products, the company provides comprehensive business-to-business services; including third-party contract manufacturing; franchise manufacturing utilizing automated softgel encapsulation technology transferred from South Korea; and wholesale distribution through its commercial subsidiary, USAR Vietnam One Member Company Limited, supported by an extensive regional retail network of GPP-certified pharmacy locations. Phong Phu Pharmaceutical distributes its products nationwide across all 63 provinces and cities in Vietnam, serving public and private hospitals, clinics, national pharmacy chains, and independent dispensaries. In recent strategic developments, the company has initiated capital investments under its 2025–2030 strategic plan to upgrade the USARICHPHARM manufacturing facilities and Quality Control laboratories, highlighted by the deployment of a dedicated GMP-standard botanical extraction production line to secure active ingredient autonomy for high-value herbal pharmaceuticals. Additionally, the company completed a leadership reorganization with the election of its Board of Directors and Supervisory Committee for the 2025–2030 term, upgraded its nationwide direct distribution management network, executed consecutive 15 percent cash dividend payouts for the 2024 and 2025 financial years, and expanded domestic and international contract manufacturing alliances.